Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive versus standard serum urate target therapy for erosive gout
ACTRN12615001219572Phase 4Completed
- Sponsor
- The University of Auckland
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of allopurinol, probenecid, febuxostat and benzbromarone in gout (2 arms), sponsored by The University of Auckland. Primary endpoint: Change from baseline in total CT erosion score. Started Mar 2016; status: completed.
02
Drugs
allopurinolprobenecidfebuxostatbenzbromarone
03
Conditions
gout
Beyond the preview
Go deeper on ACTRN12615001219572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001219572.